The Patent Finder

Zen-Bio, Inc.

Also on record
Records under this name other than patents Zen-Bio, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Back to Zen-Bio, Inc.

PatentTitleStatus Expires Confidence
US 11,795,648Paving-related measuring device incorporating a computer device and communication element therebetween and associated method
Formerly held
Term ended
Term ended Apr 22, 2023 · From the USPTO record
Term endedTerm ended Apr 22, 2023From the USPTO record
US 6,555,374Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof
Formerly held
Term ended
Term ended Dec 10, 2020 · From the USPTO record
Term endedTerm ended Dec 10, 2020From the USPTO record
US 6,242,200Screening for SUR1 antagonists using adipocytes
Formerly held
Term ended
Term ended Jun 12, 2020 · From the USPTO record
Term endedTerm ended Jun 12, 2020From the USPTO record
US 6,391,297Differentiation of adipose stromal cells into osteoblasts and uses thereof
Formerly held
Term ended
Term ended May 19, 2020 · From the USPTO record
Term endedTerm ended May 19, 2020From the USPTO record
US 6,429,013Use of adipose tissue-derived stromal cells for chondrocyte differentiation and cartilage repair
Formerly held
Term ended
Term ended May 17, 2020 · From the USPTO record
Term endedTerm ended May 17, 2020From the USPTO record
US 9,200,255Differentiation of adipose stromal cells into osteoblasts and treating bones
Formerly held
Lapsed on the fee record
Ended Dec 1, 2019 · From the USPTO record
Lapsed on the fee recordEnded Dec 1, 2019From the USPTO record
US 8,048,673Use of adipose tissue-derived stromal cells for chondrocyte differentiation and cartilage repair
Formerly held
Lapsed on the fee record
Ended Nov 1, 2019 · From the USPTO record
Lapsed on the fee recordEnded Nov 1, 2019From the USPTO record
US 6,100,047Modulation of the sulfonylurea receptor and calcium in adipocytes for treatment of obesity/diabetes
Formerly held
Term ended
Term ended Apr 7, 2019 · From the USPTO record
Term endedTerm ended Apr 7, 2019From the USPTO record
US 6,492,130Modulation of the sulfonylurea receptor and calcium in adipocytes for treatment of obesity/diabetes
Formerly held
Term ended
Ended no later than Apr 7, 2019 · From the USPTO record
Term endedEnded no later than Apr 7, 2019From the USPTO record
US 6,569,633Modulation of the sulfonylurea receptor and calcium in adipocytes for treatment of obesity/diabetes
Formerly held
Term ended
Ended no later than Apr 7, 2019 · From the USPTO record
Term endedEnded no later than Apr 7, 2019From the USPTO record
10 of 17 patents shown.
Pro members see all 17.
Pro members: see all 17 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited